Skip to main content
Full access
Editorials
Published Online: 1 May 2022

Cannabis and Brain Health: What Is Next for Developmental Cohort Studies?

Publication: American Journal of Psychiatry
Cannabis is the third most widely used psychoactive substance after alcohol and tobacco. Although it is commonly perceived to be a relatively safe substance, the health risks of cannabis use remain poorly understood. Historical drug policies that criminalized cannabis users have made it difficult for researchers to study the impact of cannabis on health outcomes. One of the most important upshots of the legal regulation of alcohol and tobacco has been the development of standardized consumption units and measures, which are reliably used in research, clinical practice, and regulatory policies to quantify addictive behaviors and drug exposure. The lack of such standardized units for cannabis consumption is one reason why the scientific literature on cannabis and brain health is laden with inconsistent and marginal effects (1).
Establishing causality in science involves multiple levels of investigation and for which no single study can claim definitive proof. Only a body of literature, when considered systematically and comprehensively, can point to a causal relationship between two complex phenomena such as chronic cannabis use and brain health. Meier et al. (2) provide a convincing set of findings indicating a robust relationship between persistent and heavy cannabis use and impaired cognitive functioning. This study offers a significant contribution by evaluating the magnitude of the relationship between cannabis and cognitive functioning and shows that the cannabis-cognition link, albeit subtle from the perspective of middle adulthood years, compares to that reported for adolescent cannabis users (3), particularly in the sense that cannabis was shown to have a specific and potentially greater impact on cognitive functioning than alcohol and tobacco.
However, like other studies (4), a unique structural brain correlate of heavy cannabis use was not revealed. Instead, reduced hippocampal volume was shown to be associated with all substance use profiles, which was similarly demonstrated by a meta-analysis of 14 addiction-neuroimaging studies reprocessed and pooled through the ENIGMA-Addiction project (4). In fact, reduced hippocampal volume appears to be one of the most consistent findings across the ENIGMA Consortium studies comparing individuals with psychiatric conditions to age- and sex-matched control subjects (4). However, this general neural marker of psychopathology has yet to be fully understood and warrants further attention considering a growing body of literature revealing the importance of the general psychopathology factor (P-factor [5]) across most psychiatric conditions. With respect to the current study, the relationships between cannabis and cognition were significant across a variety of cognitive domains, suggesting a whole brain approach, potentially focusing on functional brain connectivity, might be a more promising avenue for identifying cannabis-specific brain correlates.
In light of these nonsignificant neuroimaging findings, a more important contribution of the current study was its focus on potential unmeasured confounding variables. Much like how we have transitioned to reporting standardized effect sizes, our field should pay more attention to the size of unmeasured confounding variables to better guide future studies. Why is the confounder effect so important? The authors demonstrate that across different measurement methods, persistent and heavy cannabis use is associated with a decline in cognitive functioning, relative to pre-adolescent cognitive functioning. These findings could reflect neurotoxic effects of cannabis on adolescent brain development or early adult brain degeneration. The finding that cannabis quitters also showed marginal cognitive decline further supports this conclusion and parallels findings from studies with adolescents, showing lasting effects of cannabis use on cognitive development (3). However, the authors also rightfully address the possibility of potential unmeasured confounders, which, if identified, would have to increase the average rate of cognitive decline by approximately 50% in order to be a viable third variable explanation, according to the RUC analysis. The authors wisely include important covariates in their reported analyses, such as childhood socioeconomic status, childhood temperament, and familial history of substance misuse. To build on these significant findings, we now have more clarity of the knowledge gap and its magnitude.
Two unmeasured and potentially relevant confounders were internalizing symptoms and educational attainment. According to a recent meta-analysis, the risk of developing depression is 1.37 greater for adolescents who used cannabis before the age of 18 years (6), and the cognitive consequences of major depression are well documented (7). With respect to academic achievement, a previously published longitudinal cohort, comparable to the Dunedin study in length of follow-up and rigor, showed that early onset cannabis use satisfied many conditions for causality in the pathway to adult substance use disorder (8).
The potential long-term consequences of early onset cannabis use on academic achievement (whether attributed to the direct effects of cannabis-related neurotoxicity or the indirect effects of school disciplinary actions) should not be underestimated considering the demonstrated association between educational attainment and cognitive functioning during early adulthood (8). According to one large study, an additional 5 years of education (the difference between a high school and university education) is associated with a difference of 0.2–0.4 standard deviations in cognitive performance (3–6 IQ points). Independent of an individual’s childhood educational attainment, middle age educational and occupational attainment are associated with better brain health, including functional network organization and anatomy (9). While educational attainment is less implicated in the type of cognitive decline that occurs in the later decades of life (60–80 years [8]), the size of the effect on midlife is worthy of consideration and appears of a magnitude that could explain the relationship between cannabis and midlife cognitive decline.
School suspension and police involvement are common disciplinary actions for youth cannabis use, which have secondary effects that persist into adulthood, impacting on future educational and employment status and achievements (10). Policies that marginalize or disadvantage cannabis users could potentially decrease the likelihood that cannabis users pursue higher educational and employment opportunities, which in turn are known to enhance cognitive development and protect against premature cognitive decline (9). However, few developmental cohorts have been designed to be able to study the impact of drug policies and interventions on brain health.
With more jurisdictions adopting more liberal policies toward cannabis, longstanding and unresolved questions on causality can be more comprehensively studied, for which more rigorous measures can be used, and comparisons can be made to jurisdictions with more protective or stigmatizing drug policies and practices. It is fair to say that the Dunedin study, with its outstanding retention rates, and rich and systematic assessment framework, has been at the forefront in exposing the potential health consequences of cannabis. If sustained, this study will continue to provide one of the most comprehensive investigations of the long-term effects of cannabis exposure on mental and brain health throughout the lifespan. In acknowledging the accomplishments of this far-reaching cohort study as it shifts its focus to the later stages of the life cycle, it is also time to recognize the need for a new wave of developmental cohort studies that are better designed to examine the impact of different health and drug policies on long-term mental and brain health outcomes, including inequities around such outcomes (11, 12). Our next challenge calls for similarly rigorous longitudinal studies conducted across jurisdictions that necessarily diverge in cultural and political attitudes toward addictive behaviors so that we can begin to understand how the governance of addictive substances contributes to their safe management, or harm.

References

1.
Batalla A, Bhattacharyya S, Yuecel M, et al: Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings. PLoS One 2013; 8:e55821
2.
Meier MH, Caspi A, Knodt AR, et al: Long-term cannabis use and cognitive reserves and hippocampal volume in midlife. Am J Psychiatry 2022; 179:362–374
3.
Morin JG, Afzali MH, Bourque J, et al: A population-based analysis of the relationship between substance use and adolescent cognitive development. Am J Psychiatry 2019; 176:98–106
4.
Navarri X, Afzali MH, Lavoie J, et al: How do substance use disorders compare to other psychiatric conditions on structural brain abnormalities? A cross-disorder meta-analytic comparison using the ENIGMA consortium findings. Hum Brain Mapp 2022; 43:399–413
5.
Castellanos-Ryan N, Struve M, Whelan R, et al: Neural and cognitive correlates of the common and specific variance across externalizing problems in young adolescence. Am J Psychiatry 2014; 171:1310–1319
6.
Gobbi G, Atkin T, Zytynski T, et al: Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in young adulthood: a systematic review and meta-analysis. JAMA Psychiatry 2019; 76:426–434. Erratum in: JAMA Psychiatry 2019; 76:447
7.
Afzali MH, Oleary-Barrett M, Séguin JR, et al: Effect of depressive symptoms on the evolution of neuropsychological functions over the course of adolescence. J Affect Disord 2018; 229:328–333
8.
Rioux C, Castellanos-Ryan N, Parent S, et al: Age of cannabis use onset and adult drug abuse symptoms: a prospective study of common risk factors and indirect effects. Can J Psychiatry 2018; 63:457–464
9.
Lövdén M, Fratiglioni L, Glymour MM, et al: Education and cognitive functioning across the life span. Psychol Sci Public Interest 2020; 21:6–41
10.
Magier M, Patte KA, Battista K, et al: Are school substance use policy violation disciplinary consequences associated with student engagement in cannabis? Int J Environ Res Public Health 2020; 17:5549
11.
Zuckermann AME, Battista KV, Bélanger RE, et al: Trends in youth cannabis use across cannabis legalization: data from the COMPASS prospective cohort study. Prev Med Rep 2021; 22:101351
12.
Madia JE, Obsuth I, Thompson I, et al: Long-term labour market and economic consequences of school exclusions in England: evidence from two counterfactual approaches. Br J Educ Psychol (Epub ahead of print, Feb 9, 2022).

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 317 - 318
PubMed: 35491566

History

Accepted: 21 March 2022
Published online: 1 May 2022
Published in print: May 2022

Keywords

  1. Substance-Related and Addictive Disorders
  2. Cannabis
  3. Development
  4. Neuroimaging
  5. Cognition/Learning/Memory

Authors

Details

Patricia J. Conrod, Ph.D. [email protected]
Department of Psychiatry and Addiction, University of Montreal, CHUSJ Research Centre, Montreal, Canada.

Notes

Send correspondence to Dr. Conrod, Tier 1 Canada Research Chair in Preventive Mental Health and Addiction ([email protected]).

Competing Interests

The author reports no financial relationships with commercial interests.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share